Ribomic, Inc. (JP:4591)
:4591
Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥72.00 - ¥141.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)477.44K
Market Cap
¥4.19B
Enterprise Value¥2.03B
Total Cash (Recent Filing)¥2.81B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.64
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,072,640
10 Day Avg. Volume531,790
30 Day Avg. Volume477,440
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)1.30
Price to Sales (P/S)1880.02
P/FCF Ratio-3.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially reduces Ribomic’s fixed financial obligations and interest burden, preserving flexibility to allocate capital to R&D and partnership activity. For an early-stage biotech this lowers bankruptcy risk and makes future equity or partnership financing less encumbered by leverage.
Proprietary Aptamer PlatformA proprietary aptamer platform and focused pipeline in ophthalmology and rare diseases is a durable competitive asset: platforms can generate multiple candidate programs, increase bargaining power with partners, and support recurring licensing or royalty streams if clinical success is achieved across indications.
Partnership-driven Revenue ModelA licensing and collaboration model is capital-light and scalable: it enables program advancement via partner funding, provides milestone and royalty upside without sole commercialization capital, and aligns incentives with larger pharma partners—supporting growth while limiting upfront capex needs.
Bears Say
Minimal And Volatile RevenueRevenue profile shows almost no commercial traction—one year of zero revenue and only ≈¥2.1M in FY2025—reducing predictability and making it hard to demonstrate market demand or negotiate strong partnership economics. Sustained weak revenue limits internal reinvestment capacity.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits signal ongoing cash burn and reliance on external financing to fund operations and trials. Even with some improvement in FY2025, free cash flow remains near net losses, constraining runway and increasing the likelihood of dilutive capital raises over time.
Erosion Of Equity And Negative ROEMeaningful declines in shareholders’ equity and persistently negative returns on equity reflect cumulative losses that erode the capital base. A shrinking equity cushion reduces financial resilience, limits strategic optionality, and raises solvency and dilution risks if operational losses continue.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥72.00 and its highest was ¥141.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.19B.
When is Ribomic, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ribomic, Inc.’s earnings last quarter?
Currently, no data Available
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 55,072,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Linical Co., Ltd.
―
CanBas Co., Ltd.
―
Takara Bio Inc.
―